MILAN, Oct. 10, 2026 /PRNewswire/ -- From October 06 to   08, 2026, Kexing Biopharm (688136.SH) exhibited at CPHI Milan 2026,   showcasing its global innovative drug pipeline, co-developed biosimilars, and   a broad portfolio of products commercialized in overseas markets. During the   event, the Company engaged with drug purchasers, biotechs, and industry   partners from around the world.

In recent years,   the Company has established a relatively mature overseas commercialization   platform, and has reached overseas cooperation agreements on more than 30   products with multiple domestic pharmaceutical companies, covering   therapeutic areas such as oncology, autoimmune diseases, and metabolic   diseases, with its marketing network covering approximately 70 countries and   regions, and has submitted nearly 200 registration applications overseas.

Europe is one of   the company's key markets for the core product albumin-bound paclitaxel,   which is already marketed in the EU, the UK, and other regions. Guided by   unmet clinical needs and market potential, Kexing Biopharm is also developing   more than 10 high-value biosimilars for global markets.

To strengthen   its local presence in Europe, the Company has established a subsidiary in   Germany and is steadily advancing plans to set up subsidiaries in France,   Spain, Italy, the United Kingdom, the Netherlands, and other markets. These   local operations will enable Kexing Biopharm to respond more effectively to   regional customer needs and build long-term relationships with its partners.   The Company's participation in CPHI events in Europe over consecutive years   has provided an important platform for deepening its presence in the region   and engaging face-to-face with local industry partners.

"Innovation+   internationalization" is the Company's core strategic direction, and   among the innovative drug pipeline displayed on site, research progress in   areas such as cancer cachexia, ophthalmic drugs, systemic lupus erythematosus   (SLE), and inflammatory bowel disease (IBD) has drawn the attention of   visitors, with multiple pipelines targeting long-term chronic disease markets   and unmet clinical needs.

Product quality   is the foundation of successful global expansion. With 30 years of   industrial-scale experience in biopharmaceuticals, Kexing Biopharm has   established mature manufacturing and quality management systems. Its   manufacturing line for albumin-bound paclitaxel has received EU GMP   certification, and the product has been approved in more than 40 countries   and regions.

Looking ahead,   Kexing Biopharm will continue to advance the innovation and commercialization   of high-quality medicines. Together with partners worldwide, the Company is   committed to contributing to better health for people around the world.

記事の表示...